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Abstract
Background: Eradication of Helicobacter pylori is an important objective in overcoming gastric
diseases. Many regimens are currently available but none of them could achieve 100% success in
eradication. Eugenol and cinnamaldehyde that are commonly used in various food preparations are
known to possess antimicrobial activity against a wide spectrum of bacteria.
Aim: The present study was performed to assess the in vitro effects of eugenol and cinnamaldehyde
against indigenous and standard H. pylori strains, their minimum inhibitory concentrations (MICs)
and time course lethal effects at various pH.
Methods: A total of 31 strains (29 indigenous and one standard strain of H. pylori ATCC 26695,
one strain of E. coli NCIM 2089) were screened. Agar dilution method was used for the
determination of drug sensitivity patterns of isolates to the commonly used antibiotics and broth
dilution method for the test compounds.
Results: Eugenol and cinnamaldehyde inhibited the growth of all the 30 H. pylori strains tested, at
a concentration of 2 µg/ml, in the 9th and 12th hours of incubation respectively. At acidic pH,
increased activity was observed for both the compounds. Furthermore, the organism did not
develop any resistance towards these compounds even after 10 passages grown at sub-inhibitory
concentrations.
Conclusion: These results indicate that the two bioactive compounds we tested may prevent H.
pylori growth in vitro, without acquiring any resistance.
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Introduction
Helicobacter pylori was first discovered in 1982 and was
subsequently found to be an important etiological agent
for gastritis [1], peptic ulcers [2] and gastric malignancy
[3]. It is estimated that one-half of the world's population
is infected with H. pylori [4]. Numerous clinical evidences
reveal that eradication of H. pylori results in improvement
of gastritis and drastically decreases the rate of relapse of
gastric and duodenal ulcers [5,6]. H. pylori carriage rates
are about 80–90% in developing countries [7], with a
high risk of gastric cancer and antibiotic regimens against
H. pylori are frequently ineffective in such populations [8].
Besides this, undesirable side effects [9], noncompliance
among the patients [10] and the cost of the antibiotic reg-
imens [11] are few other factors for their ineffectiveness.
Hence there is a need to develop alternative approaches to
suppress/cure the infection.
Since ancient times, spices and condiments have been
considered indispensable in the culinary arts, as they are
used to flavor foods. Also these spices were recognized for
their physiological and medicinal properties. It is pre-
sumed that the broad-spectrum effectiveness of these
spices [12-14] may provide a suitable basis for new anti H.
pylori therapies. Some of the epidemiological studies sug-
gest an inverse relationship between the occurence of can-
cer of stomach (for which H. pylori infection is a known
risk factor) and the intake of the allium vegetables
[15,16]. There are reports on in vitro antimicrobial activity
of many spice extracts (and not their active principles) on
H. pylori [17,18]. But active principles of garlic and garlic
components have been tried [11,19].
Eugenol, a phenolic compound is the main component of
clove (Eugenia caryophillis) oil. Cinnamaldehyde is an aro-
matic aldehyde and main component of bark extract of
cinnamon (Cinnamomum verum). Both these compounds
are present in essential oils of many plants and are proved
to be active against many pathogenic bacteria [20,21],
fungi [21,22] and viruses [14]. There is a paucity of infor-
mation on the effects of these bioactive compounds on H.
pylori. Therefore, the present study was undertaken to eval-
uate the efficacy of eugenol and cinnamaldehyde as anti
H. pylori agents.
Materials and methods
H. pylori strains
Thirty H. pylori strains and one E. coli strain (NCIM2089)
were used in the study. Twenty-nine strains that were des-
ignated as MS-1 to MS-29 were isolated from gastric
biopsy specimens (15 from duodenal ulcer, 10 from non
ulcer dyspepsia and 4 from gastric ulcer subjects), after
informed consents from patients who have undergone
upper gastrointestinal endoscopy at Deccan College of
Medical Sciences, Hyderabad, India. One strain of H.
pylori (ATCC26695) was also included.
Primary isolation was performed on Brucella agar (Bec-
ton, Dickinson & Co, Sparks, USA), supplemented with
7% (V/V) sheep blood and antibiotics (Vancomycin, 6
mg/L; Amphoteracin B, 3 mg/L; Polymixin B, 2500 IU/L;
Hi-Media, Mumbai, India). Final pH of the media was
adjusted to 7.2. H. pylori was identified by its typical col-
ony morphology, Gram staining, microaerophilic growth
at 37°C and by other biochemical tests such as oxidase,
catalase and urease. These strains were preserved at -80°C
in brucella broth (Becton, Dickinson & Co, Sparks, USA)
containing 10% (V/V) fetal calf serum (FCS) and 20% (V/
V) glycerol.
Bioactive compounds
Commercial preparations of bioactive compounds such
as eugenol and cinnamaldehyde were used in our experi-
ments. All the strains were seeded on Brucella agar supple-
mented with 7% sheep blood and grown for 48 hours
under microaerobic conditions. Bacterial growth was har-
vested from the plates and resuspended in sterile saline.
The inoculum was prepared to contain ~108 CFU/ml by
adjusting the suspension to match the McFarland No-4
turbidity standard [23].
Antibacterial activity of standard antibiotics
Minimum inhibitory concentrations (MICs) for antibiot-
ics like metronidazole, amoxycillin and clarithromycin
were determined by agar dilution method, using two fold
increments (0.016 to 256 µg/ml) on Mueller Hinton agar
(MHA) plates supplemented with 7% sheep blood and
incubated for 3 days at 37°C in a microaerophilic cabinet.
MICs were determined as the lowest concentration of the
antibiotics inhibiting visible growth [24] using ~106 CFU
of inoculum.
Antibacterial activity of eugenol and cinnamaldehyde
Primary screening
The Kirby-Bauer disk diffusion susceptibility test was used
to check the activity of the bioactive compounds on H.
pylori. The inoculum prepared as described previously was
inoculated onto MHA supplemented with 7% sheep
blood and bioactive compound discs (prepared by load-
ing the respective compounds in variable concentration
on to the sterile filter paper discs) were placed on to the
plates with the sterile dispenser and incubated in micro-
aerobic atmosphere at 37°C for 3 days.
Minimum inhibitory concentration (MIC) of bioactive compounds
As there was no established method to determine the anti-
bacterial activity of bioactive compounds against H. pylori,
serial two fold dilutions of eugenol and cinnamaldehyde
were made in a 5 ml Brucella broth preparation (pH-7)Annals of Clinical Microbiology and Antimicrobials 2005, 4:20 http://www.ann-clinmicrob.com/content/4/1/20
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with 0.1% dimethyl sulfoxide (DMSO; that enhances
compound solubility) and supplemented with 2.5% fetal
calf serum (FCS). Cotton-wool plugged 25 ml conical
flasks of Brucella broth prepared as above, were inocu-
lated with H. pylori (~106 CFU/ml)[11]. The flasks were
incubated for 3–5 days in a microaerophilic cabinet with
shaking at ~150 rpm. Following incubation, 100 µl aliq-
uots of the medium were plated onto brucella agar plates
supplemented with 7% sheep blood to determine the via-
ble counts.
Time Course
Time course viability studies of the bioactive compounds
were set up in the same way as the above MIC tests, but the
broths were sampled hourly over the first 4 h and then
again at 6, 9, 12, 24, 48 and 72 h to check the viable count.
H. pylori ATCC26695 was used as the inoculum for the
study.
For comparison, known antibiotic such as amoxycillin
was used and E. coli (NCIM2089) was used as a standard
bacterial control other than H. pylori.
Effects of bioactive compounds on H. pylori morphology
To check the effect of bioactive compounds on the mor-
phology of H. pylori, slides were prepared from the above
samples of first four hours, stained with Giemsa and
observed under oil immersion.
Measurement of bactericidal activity at acidic pH
The effects of pH on the antibacterial activities of eugenol
and cinnamaldehyde were done as reported previously
[25,26]. The pH of the buffer was adjusted to 4.00 using
100 mM citrate buffer (pH 5.2) supplemented with 10
mM urea and the pH was adjusted to 7.00 using 10 mM
phosphate buffer (pH 6.8). H. pylori ATCC26695 (~107
CFU/ml) was inoculated into 5 ml of the medium with
0.1% DMSO to which various concentrations of the com-
pounds were added. All the flasks were incubated at 37°C.
Twenty µL of the samples were taken at 0, 15, 30 and 60
minutes after inoculation to enumerate the number of
viable cells.
Test for development of resistance to bioactive 
compounds
To investigate the development of resistance, five strains
i.e. ATCC26695, MS-27 (sensitive to all the three antibiot-
ics), MS-1 (resistant to all the three antibiotics), MS-8
(resistant to metronidazole, clarithromycin and sensitive
to amoxycillin), and MS-15 (resistant only to metronida-
zole), were grown on agar at sub inhibitory concentra-
tions (0.25 and 0.5 µg/ml) of eugenol and
cinnamaldehyde for 10 passages. All the experiments
stated above were repeated three times.
Results
Antibacterial activity against H. pylori
MICs of antibiotics for H. pylori were determined. Strain
ATCC26695 was sensitive (MIC < 0.016 µg/ml) to all the
three drugs tested. Twenty (66.7%) clinical isolates (MS1-
8, 10, 12, 14 – 17, 20, 23 – 26 and MS28) from our labo-
ratory were resistant to metronidazole (MICs > 8 µg/ml),
2 (6.7%) clinical isolates (MS1 & 8) were resistant to clar-
ithromycin (MICs > 2 µg/ml) and 1 (3.3%) clinical isolate
(MS1) was resistant to amoxycillin (MIC > 0.5 µg/ml)
[27] (Table 1).
In the preliminary screening, both the compounds gave
approximately 15 mm inhibition zones to all the clinical
isolates and standard strain (H. pylori ATCC26695). This
Time course viability studies of eugenol and cinnamaldehyde  with H. pylori ATCC26695 Figure 1
Time course viability studies of eugenol and cin-
namaldehyde with H. pylori ATCC26695. ATCC26695 
was exposed to eugenol at concentrations of (◆ ) 4 µg/ml, 
(■ ) 2 µg/ml, (▲ ) 1 µg/ml, (● ) control, and to cinnamalde-
hyde () 4 µg/ml, () 2 µg/ml, () 1 µg/ml. Detection limit 
was shown with a straight line. The controls were maintained 
with 0.1% DMSO.
Table 1: Sensitivity of H. pylori strains (n = 30) to different antibiotics
Antibiotic Sensitive (%) Resistance (%) Range (µg/ml) MIC27 (µg/ml)
Metronidazole 10 (33.3) 20 (66.7) <0.5 – >256 >8
Clarithromycin 28 (93.3) 2 (6.7) <0.5 – >256 >2
Amoxycillin 29 (96.7) 1 (3.3) <0.5 – >256 >0.5Annals of Clinical Microbiology and Antimicrobials 2005, 4:20 http://www.ann-clinmicrob.com/content/4/1/20
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in vitro antimicrobial effect of the bioactive compounds
demonstrated that both the compounds were capable of
completely inhibiting the growth of all the strains (both
sensitive & resistant) at a concentration of 2 µg/ml. For E.
coli (NCIM-2089), MIC of eugenol and cinnamaldehyde
was 1 µg/ml.
Time course
As both the compounds were active at a concentration of
2 µg/ml, we examined the killing curve time course of
both the compounds at different concentrations i.e. 1 µg/
ml, 2 µg/ml and 4 µg/ml. Eugenol completely inhibited
the growth of H. pylori ATCC 26695 at 2 µg/ml concentra-
tion in 9 hours of incubation. The growth was completely
inhibited in only 6 hours when the MIC was doubled (4
µg/ml). Some inhibition of growth was observed at the
MIC of 1 µg/ml, where up to 6th hour a decrease of ~1.6
Log was observed then afterwards there was no effect of
the compound on the bacterium (Figure 1). Cinnamalde-
hyde inhibited ATCC26695 totally at 2 µg/ml in 12 hours
and in 9 hours at double the MIC (4 µg/ml). However, at
half of the MIC (1 µg/ml), a little effect was observed up
to the 3rd hour and there was a decrease of 0.6 Log with no
subsequent inhibitory effect (Figure 1).
The time course lethal action of the bioactive compounds
on E. coli (NCIM-2089) was studied at three different con-
centrations (1 µg/ml, 2 µg/ml & 0.5 µg/ml). At 1 µg/ml,
eugenol inhibited E. coli after 1 hour of incubation
whereas cinnamaldehyde inhibited E. coli after 75 min-
utes of incubation (Figure 2).
For comparing the efficacy of our bioactive compounds
against H. pylori, we studied the effect of a common anti-
biotic (amoxycillin) at different concentrations such as 1
µg/ml, 0.1 µg/ml and 0.01 µg/ml with an MIC of < 0.016
µg/ml. There was no inhibition of H. pylori seen at the
concentration of 0.01 µg/ml. But inhibition was noticed
at a concentration of 0.1 µg/ml up to the 4th hour of incu-
bation. However, the bacterium was completely inhibited
at a concentration of 1 µg/ml, by the 12th hour of incuba-
tion (Figure 3).
H. pylori morphology
Microscopic observation of slides revealed that at high
concentrations of both the bioactive compounds (4 µg/
ml) and after 4 hours of incubation, ~70% of the cells
assumed coccoid forms with fewer spiral shaped organ-
isms.
Effect of the bioactive compounds on the growth of H. 
pylori in buffers at acidic pH
The viability of strain ATCC 26695 at acidic pH was inves-
tigated using eugenol and cinnamaldehyde at various
concentrations (2 µg/ml, 4 µg/ml and 1 µg/ml). As shown
in Figure 4, both the compounds revealed increased activ-
ity at acidic pH (pH-4.0) and a dose dependant bacteri-
cidal activity was also observed. At a concentration of
double the MIC (4 µg/ml), eugenol was found to com-
pletely inhibit the bacteria at about 1 hour of incubation.
Cinnamaldehyde also revealed bactericidal activity in the
similar manner but did not inhibit the organism totally
(after one hour of incubation there was a difference of 0.2
Log). For both the compounds, when compared at acidic
and neutral pH, we found a Log difference of 1.5 after one
hour of incubation at MIC of 2 µg/ml.
Test for resistance to eugenol and cinnamaldehyde
We investigated whether H. pylori would acquire resist-
ance to the bioactive compounds. Selected H. pylori strains
(ATCC26695, MS-27, MS-1, MS-8 and MS-15) did not
acquire resistance to both the bioactive compounds at sub
inhibitory concentrations (0.25 and 0.5 µg/ml) even after
10 passages.
Discussion
Eradication of H. pylori with monotherapy is difficult and
often results in poor clinical outcome [28]. Presently a
proton pump inhibitor (PPI) based triple therapy is being
used. Though it is having a success rate of 80 to 90% [29],
problems like treatment failure and contraindications for
some patients are common. Furthermore, the major prob-
lem in treating H. pylori infection is rapidly emerging drug
resistance during treatment with various antibiotics [30].
Effects of eugenol and cinnamaldehyde on the growth of E.  coli NCIM-2089 Figure 2
Effects of eugenol and cinnamaldehyde on the 
growth of E. coli NCIM-2089. E. coli was exposed to euge-
nol at concentrations of (◆ ) 2 µg/ml, (■ ) 1 µg/ml, (Њ) 0.5 
µg/ml, (● ) control, and to cinnamaldehyde at concentrations 
of ()2 µg/ml, () 1 µg/ml, () 0.5 µg/ml. Detection limit 
was shown with a straight line. The controls were maintained 
with 0.1% DMSO.
Time course lethal action of Eugenol and
Cinnamaldehyde against E. coli NCIM2089
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Because of the prevalence of antibiotic-resistant H. pylori
strains, the search for safe and effective non-antibiotic
agents is essential.
In Indian traditional medical system, a number of plants
and plant products are known to possess potent medici-
nal properties, suggesting that plants, plant products and
their extracts may be useful for specific medical condi-
tions. Hence in our effort to identify newer compounds,
which can inhibit H. pylori growth, we tested eugenol and
cinnamaldehyde. These compounds have already been
found to inhibit 10 different multi drug resistant patho-
genic bacteria such as E. coli, Staphylococcus, Proteus, Kleb-
siella, Enterobacter, and Pseudomonas isolated from human
subjects [20,21]. In our studies, eugenol and cinnamalde-
hyde completely inhibited all the strains (both sensitive &
resistant) at a concentration of 2 µg/ml. This inhibitory
concentration is very less when compared against the pre-
viously reported MICs {allicins: 6–12 µg/ml, garlic oil: 8–
32 µg/ml [11] and ajoenes: 10–25 µg/ml [31]}. Our com-
pounds also proved to be more potent than thiosulfinate
{40 µg/ml [19]}, vinyldithiins {<100 µg/ml [31]}, epigal-
locatechin gallate {50–100 µg/ml [32]} and garlic pow-
der {250 µg/ml [11]}.
In time course viability studies, we found that eugenol
and cinnamaldehyde inhibited H. pylori ATCC26695 at 2
µg/ml concentration within 9 and 12 hours of incubation
respectively. Highly potent effects of some essential oils of
lemon grass on H. pylori have been previously described
[26]. However, our observations may be more accurate
with the fact that we used active principles and not the
extracts or oils as used by Ohno et al., [26]. These essential
oils may contain unknown substances that might provide
synergistic, inhibitory effects. Eugenol in our studies was
found to be a potent antimicrobial than the essential oils
of Ohno and colleagues [26] whereas the effect of cin-
namaldehyde was approximately equivalent to the oils
used by them. Further, our compounds were more potent
than the common antibiotic amoxycillin, which inhibited
H. pylori ATCC26695 at 12th hour (similar to cinnamalde-
hyde) whereas eugenol inhibited microbial growth at the
9th hour of incubation itself, at its minimum inhibitory
concentration. Amoxycillin was found to completely
inhibit bacteria at a higher concentration (1 µg/ml), than
it's minimum inhibitory concentration (0.016 µg/ml)
(Figure 3). As H. pylori resides in the stomach, where pH
levels are lower than 3.0, it is important to check the activ-
ity and stability of a compound at acidic pH. In our study,
H. pylori isolates survived at pH 4.0, despite some reports
showing H. pylori survival at pH-3.0 [25], and bactericidal
effects of the bioactive compounds were found to be
stronger even at low pH. Several agents that have bacteri-
cidal effects against H. pylori are dependent on pH (for
example, ecabet sodium is active at acidic pH [25] and tea
cathechin is active at alkaline pH [33]).
Furthermore, we found that the organism did not develop
any resistance to the test compounds even after 10 succes-
sive passages grown at sub-inhibitory concentrations
(0.25 and 0.5 µg/ml) [21], whereas H. pylori strains
acquired resistance to amoxycillin and clarithromycin
Effect of eugenol and cinnamaldehyde on the growth of H.  pylori (ATCC26695) at low pH Figure 4
Effect of eugenol and cinnamaldehyde on the growth 
of H. pylori (ATCC26695) at low pH. ATCC26695 was 
exposed to eugenol at pH4 (solid lines) and pH7 (dotted 
lines) at concentrations (◆  or ) 4 µg/ml, (■  or ) 2 µg/ml, 
(Њ or ) 1 µg/ml, (● ) control. Detection limit was shown as 
a straight line. The controls were maintained with 0.1% 
DMSO.
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Effect of amoxicillin on the growth of H. pylori (ATCC26695) Figure 3
Effect of amoxicillin on the growth of H. pylori 
(ATCC26695). ATCC26695 was exposed to at concentra-
tions of () 1 µg/ml, (■ ) 0.1 µg/ml, (▲ ) 0.01 µg/ml, (❍ ) con-
trol. Detection limit was shown with a straight line.Annals of Clinical Microbiology and Antimicrobials 2005, 4:20 http://www.ann-clinmicrob.com/content/4/1/20
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after 10 sequential passages as reported previously
[26,34]. In addition, these bioactive compounds had
equivalent bactericidal activities against both the suscepti-
ble and resistant H. pylori strains.
Eugenol and cinnamaldehyde form a part of regular diet
in tropical countries since ages. Many reports suggest
these compounds are nontoxic at doses being consumed
[34], and they are known for their antimicrobial and anti-
oxidant properties [21,36]. Moreover, to heal peptic ulcer,
or to prevent the oxidative stress, prescribing antioxidants
is quite a normal practice these days with the medical
practitioners. As both these compounds are natural anti-
oxidant [37], their benefits could be multiple. Two animal
studies carried out in the past suggest that an extract of
cinnamon bark taken orally may help prevent stomach
ulcer [36] and one study described eugenol to be both
anti-inflammatory and antiulcerogenic [38]. It was used
as early as 1950 for treating ulcer disease [39]. Given all
the advantages we observed for the two bioactive com-
pounds tested, our data should not be construed as certi-
fication of the compounds in clinical application until
their stability, specificity and overall efficacy is established
in different laboratories and against different bacterial
strains. Further studies are therefore clearly needed in the
context of reproducibility of these findings under different
laboratory conditions.
Conclusion
The data obtained in this study show that eugenol and
cinnamaldehyde at 2 µg/ml produce significant decrease
of viability of the organism H. pylori, irrespective of the
strain. Activity of these compounds at low pH levels may
help them achieve their efficacy in an environment such
as human stomach. We trust these findings are encourag-
ing in view of growing treatment failures and antibiotic
resistance in the area of H. pylori management. Additional
in vivo studies and clinical trials would be needed to justify
and further evaluate the potential of these compounds as
anti H. pylori agents.
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